Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys


BMSystems' Group Profile

  • Independent Private Company incorporated in 2004, profitable since 2006.
  • 100% owned by its founders (no search for external investors for BMSystems company, open for its spin-offs).
  • The first Mechanisms-Based Medicine company that discovers novel diagnostic, therapeutic & prevention solutions.
  • A clear “Biology” driven company that intensively uses I.T. resources. Inventor and exclusive owner of all its technologies.
  • 24 vFTE* of which 9 vFTE scientists/professionals focused on CADI**™ research.
  • Long term strategic R&D and business collaborations with more than 100 partners’ professionals working on BMSystems’ related R&D programs.
  • Original dual business model that generates revenues through contractual R&D programs & patented novel therapeutic & prevention solutions through collaborative R&D programs with its partners.
  • Company strictly focus on Discovery, the validation phases and the patented discoveries developments are implemented outside the company with selected partners.
  • The largest IT life sciences and healthcare business offer with its strategic IT partner, Persistent Systems (Leading Indian IT company 7000 people, 250 M$, 85% of business in the USA).
  • Member of BiO (USA), MEDICEN (Health, IAR (Industrial biotech) clusters.
  • Member in France of Leem Biotech, Adebiotech, Medef, Centrale-Santé Think Tanks.
  • Founders, member of international organizations (HUGO, CHI, etc…).
  • A responsible Innnovation© company

 BMSystems' Science at a glance

  • Understanding the causal mechanisms of a disease is the first objective. Finding the most adapted biomarkers and solutions are the necessary consequences of the first objective.
  • BMSystems invented CADI™ Discovery in 2004, the first operational "Mechanisms-based Medicine" platform, dedicated to the discovery of cost-effective new diagnostic, therapeutic and prevention solutions for medicine, cosmetics, etc, ...
  • BMSystems' team builds heuristic non-mathematical in-silico models to generate novel disruptive concepts from scientific, medical & health data.
  • CADI™ Discovery and the competition download the document
  • CADI™ Discovery addresses both efficacy and safety issues, the main culprits for the unacceptable R&D attrition rate.
  • BMSystems already generated a significant pipeline of internal Research programs.
  • CADI™ patented novel therapies, already contributed to the creation of two funded Pharma SMEs at clinical stage.:

 BMSystems' dual business model:

  • BMSystems separates its CADI™ research (internal) from the outputs developments (external).
  • BMsystems does not sell its technologies nor give access to them.
  • BMSystems sells the outputs of its research programs to its clients through contractual research programs (options: Access, fees, success fees, Discovery fees).
  • BMSystems shares the outputs of its research programs to its partners through collaborative research programs (each partner finances its costs, shares IP, defines together the development options).
  • The contractual and collaborative businesses are limited to 50% each to secure long run business.
  • BMSystems has repeatedly proven to create business value from its unique new research paradigm.
  • A responsible Innnovation© process

*vFTE (varaible Full Time Equivalent)

Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology Mechanisms-Based Medicine company that delivers